Abbott, Thermo Fisher Scientific Inc., Shimadzu Corporation are dominating the Global Parasitology Identification Market in 2018

Global Parasitology Identification Market is expected to grow at a healthy CAGR of 10.9% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below:

Access Full Report at

Global parasitology identification market is an upcoming market which includes key players and local players. The market is growing owing to the favourable market scenario. The market has a prominent growth in upcoming years due to increasing R&D expenditure and technological advancements in the identification techniques. The market has witness developments in terms of merger and acquisitions or product launches to enhance the product portfolio to meet the rising demand of parasitology identification market. For instance, In April 2019, altonaDiagnostics GmbH had announced the product launch of AltoStar HEV RT-PCR Kit 1.5. The product is used to detect and quantify the hepatitis E virus (HEV) specific RNA.

Abbott dominated the global parasitology identification market. The other key players in the market are Meridian Bioscience Inc., Orgentec Diagnostika GmbH, Trinity Biotech, VWR International, LLC., Eurofins Scientific, Tecan Trading AG, BD, Thermo Fisher Scientific Inc., VIRION/SERION, altona Diagnostics GmbH, Bio-Rad Laboratories, Inc., Quest Diagnostics Incorporated, Shimadzu Corporation, Luminex Corporation, Creative Diagnostics, Bruker, bioMérieux SA, Liferiver Bio-Tech (United States) Corp., Biomerica, Inc., R-Biopharm and others.


Abbott headquartered in Illinois, U.S. was founded in 1888. The company manufactures products for diagnostics, medical devices, nutrition and branded generic pharmaceuticals. The company have 5 business segments which are established pharmaceuticals, nutritionals, diagnostics, cardiovascular and neuromodulation and other in which diagnostics is the market focused segment.

The company has various product categories such as cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition, medicines in which diagnostics is the market focused category. The company has 103,000 total number of employees.     

  • In October 2019, Abbott announced the acquisition of Alere (U.S.). This acquisition helped Abbott to strengthen its product portfolio. The Alere (U.S.) is the leading point care test leader and acquisition will help in strengthen the business for in vitro diagnostics.

It has its global networks through direct sales representatives and distributors in the Americas, Asia-Pacific, Europe, Middle East and South Africa. The company’s subsidiaries include Alere Inc. (U.S.), Abbott Medical Optics Inc. (U.S.), EAS (U.S.), Abbott India Ltd (India), Thoratec Corporation(U.S.), Abbott Informatics (U.S.), CardioMEMS (U.S.), CFR Pharmaceuticals (Chile), Abbott GmbH & Co. KG (Germany) and many others.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc is headquartered in Massachusetts, U.S., was founded in 2006. The company mainly focuses on offering analytical, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services to accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity.

The company has 4 business segments analytical instruments, life science solutions, specialty diagnostics, laboratory products & services out of which life science solutions is market focused segment. The company has 5 main devisions which include ThermoScientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services. The company has approx. 70000 employees.

  • In June 2019, the company acquired HighChem, Ltd. which is a leading developer of the mass spectrometry software. The HighChem software solutions can be used to analyze the complex data and to identify the small molecules in metabolomics and pharmaceutical laboratories. This addition of the HighChem's software solutions with the prevailing mass spectrometry software product portfolio will allow the company in delivering greater value for the mass spectrometry customers.

It has its global networks through direct sales representatives and distributors in Asia-Pacific, Europe, Americas, Middle East and Africa. The company’s subsidiaries include Dionex (U.S.), Patheon (Netherlands), Affymetrix (U.S.), FEI Company (U.S.), Cole-Parmer (U.S.) and others.

Shimadzu Corporation:

Shimadzu Corporation headquartered in Kyoto, Japan, was founded in 1875. The company offers various analytical and measuring instruments, medical systems and equipment, industrial machinery, aircraft equipment and other equipment which can be used for a wide range of applications in various industries.

The company has 5 business segments which are analytical and measuring instruments, medical systems and equipment, industrial machinery, aircraft equipment, other. The market focused segments is analytical and measuring instruments. The company has 12,684 employees as of March 31, 2019.

  • In May 2019, the company launched MALDImini-1 which is a compact MALDI Digital-Ion Trap Mass Spectrometer. It allows fast high sensitivity measurement and detailed structural and the qualitative analyses for a broad mass range, even with the sub-microliter sample volumes. This would help in expanding the product portfolio of the company.

It has its global networks through direct sales representatives and distributors in Americas, Europe, Asia-Pacific, Middle East & Africa. The company has various subsidiaries such as Shimadzu Scientific Instruments Incorporated (U.S.), Kratos Analytical Ltd. (U.K.), Shimadzu (Hong Kong) Limited (Hong Kong), Shimadzu Analytical India Pvt Ltd (India), infraserv Vakuumservice GmbH (Germany) and others.